clinical trial · NCT04205812
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung CancerMetastatic Nonsquamous Non-Small Cell Lung CancerRetifanlimabPlaceboPemetrexedCisplatinCarboplatinPaclitaxelnab-Paclitaxel
brief summary
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
started
Sep 11, 2020
primary completion
Dec 15, 2023
completion
Aug 28, 2026
last updated
Mar 31, 2026
official title
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol